Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review

Abstract

Our comprehensive review focuses on the treatment of hepatitis C virus in the context of hepatocellular carcinoma and vice versa, highlighting the ongoing complexity of this clinical scenario. There remain multiple unanswered questions when considering the management of these complex patients and, with a rapidly-changing treatment landscape for both chronic hepatitis C and hepatocellular carcinoma, these questions are only going to grow. Treatment timing, interactions and the impact of one disease condition on the other are vitally important, though guidance generally remains non-specific, suggesting that we make these decisions on a case-by-case basis. We focus on the current evidence for managing these cases, depending on disease stage and treatment type.

Keywords

Hepatocellular carcinoma / liver cancer / hepatitis C virus / direct-acting antiviral agents

References

[1] Alazawi W,Dearden J.Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection..Aliment Pharmacol Ther2010;32:344-55

[2] Fattovich G,Zagni I,Schalm SW.Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients..Am J Gastroenterol2002;97:2886-95

[3] Kobayashi M,Hosaka T,Someya T.Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections..J Med Virol2006;78:459-65

[4] Toshikuni N,Nishino K,Sakanoue R.Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis..J Gastroenterol Hepatol2009;24:1276-83

[5] Wirth TC.The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma..Ann Oncol2016;27:1467-74

[6] Gaddikeri S,Wang CL,Dighe MK.Hepatocellular Carcinoma in the Noncirrhotic Liver..Am J Roentgenol2014;203:34-47

[7] El-Refaie A,Bhattacharya S,Harrison TJ.HCV-associated hepatocellular carcinoma without cirrhosis..J Hepatol1996;24:277-85

[8] Yeh M,Torbenson M.Hepatitis c associated hepatocellular carcinomas in non- cirrhotic livers..Mod Pathol2010;23:276-83 PMCID:PMC3037012

[9] Ray RB,Ray R.Hepatitic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma..Virology2000;271:197-204

[10] Levrero M.Viral hepatitis and liver cancer: the case of hepatitis C..Oncogene2006;25:3834-47

[11] McCombs J,Tonnu-Mihara I,Hines P.The risk of long-term morbidity and mortality in patients with chronic hepatitis c : results from an analysis of data from a department of veterans affairs clinical registry..JAMA Intern Med2014;174:204-12

[12] van der Meer AJ,Feld JJ,Dufour JF.Association between sustained virological response and all cause mortality among patients with chronic hepatitis c and advanced hepatic fibrosis..J Am Med Assoc2012;308:2584-93

[13] Cabibbo G,Barbara M,Bucci L.Hepatic decompensation is the major driver of death in hcv-infected cirrhotic patients with successfully treated early hepatocellular carcinoma..J Hepatol2017;67:65-71

[14] Heim MH.Innate immunity and HCV..J Hepatol2013;58:564-74

[15] McHutchison JG.Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C..N Engl J Med1998;339:1485-92

[16] Manns M P,Cornberg M.Treating viral hepatitis C: efficacy, side effects, and complications..Gut2006;55:1350-9 PMCID:PMC1860034

[17] Hsu CS,Lin HH,Kao JH.Systematic review: impact of interferon-based therapy on hcv-related hepatocellular carcinoma..Sci Rep2015;5:1-9 PMCID:PMC4428066

[18] Kohli A,Sherman A.Treatment of hepatitis C: a systematic review..J Am Med Assoc2014;312:631-40

[19] Geddawy A,Elbahie NM.Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction..J Transl Intern Med2017;5:8-17 PMCID:PMC5490957

[20] Putra J,Fiel MI.Histological assessment of the liver explant in transplanted hcv-patients achieving sustained virologic response with direct-acting antiviral agents..Histopathology2018;72:990-6

[21] Ahmad J,Branch AD.HCV and HCC : clinical update and a review of hcc-associated viral mutations in the core gene..Semin. Liver Dis2011;31:347-55

[22] Lok AS,Morgan TR,Sterling RK.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis c-related advanced liver disease..Gastroenterology2009;136:138-48 PMCID:PMC3749922

[23] Lok AS,Wright EC,Kim HYt.Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis c..Gastroenterology2011;140:840-9 PMCID:PMC3057272

[24] Shiffman ML,Dienstag JL,Hoefs JC.Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial..Gastroenterology2009;137:1986-94 PMCID:PMC3774149

[25] Morgan TR,Kim HY,Shiffman ML.Outcome of sustained virological responders with histologically advanced chronic hepatitis c..Hepatology2010;52:833-44 PMCID:PMC2932862

[26] Cardoso AC,Figueiredo-Mendes C,Giuily N.Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis..J Hepatol2010;52:652-7

[27] Kusano H,Ogasawara S,Yasumoto M.Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo..PLoS One2013;8:1-10 PMCID:PMC3861497

[28] Llovet JM,Bruix J.The barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma..Liver Transplant2004;10:115-20

[29] Zhang YJ,Yu XS.Effect of interferon therapy on outcomes after hepatic resection for hepatitis C virus-related hepatocellular carcinoma: a meta-analysis..Int J Clin Exp Med2016;9:1675-83

[30] Tanimoto Y,Aikata H,Oshita A.Impact of pegylated interferon therapy on outcomes of patients with hepatitis c virus-related hepatocellular carcinoma after curative hepatic resection..Ann Surg Oncol2012;19:418-25

[31] Singal AK,Anand BS.Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma..Aliment Pharmacol Ther2010;32:851-8

[32] Miao RY,Yang HY,Lu X.Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis..World J. Gastroenterol2010;16:2931-42 PMCID:PMC2887591

[33] Kushner T,Saberi B.Direct-acting antiviral treatment for patients with hepatocellular carcinoma..Curr Opin Gastroenterol2018;34:1-8

[34] Prenner SB.Hepatocellular carcinoma in the wait-listed patient with hepatitis C virus..Curr Opin Organ Transplant2018;23:237-43

[35] Saberi B,Durand CM,Cameron AM.Challenges in treatment of hepatitis c among patients with hepatocellular carcinoma..Hepatology2017;66:661-3

[36] Beste LA,Berry K,Allison SK.Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma..J Hepatol2017;67:32-9 PMCID:PMC6590903

[37] Prenner SB,Flamm SL,Lewandowski RJ.Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals..J Hepatol2017;66:1173-81 PMCID:PMC5776681

[38] Radhakrishnan K,Reddy K. Rajender,Levitsky Josh.Impact of hepatocellular carcinoma (HCC) and tumor treatment on sustained virologic response (SVR) rates with direct-acting antiviral (DAA) therapy for hepatitis C: HCV-TARGET results..Hepatology2017;66:755-6

[39] Soria A,Lapadula G.Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals..Hepatology2017;66:992-4

[40] Ji F,Wei MT,Dang S.Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: Do direct-acting antiviral regimens matter?.Hepatology2018;67:1180-2

[41] Reig M,Perelló C,Ribeiro A.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[42] Guarino M,Cossiga V,Caporaso N.Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: a few lights and many shadows..World J Gastroenterol2018;24:2582-95 PMCID:PMC6021774

[43] El-Serag HB,Richardson P.Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis c virus infection..Hepatology2016;64:130-7 PMCID:PMC4917456

[44] Waziry R,Grebely J,Law M.Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression..J Hepatol2017;67:1204-12

[45] Ioannou GN,Berry K.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma..J Hepatol2018;68:25-32

[46] Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT03551444 [Last accessed on 27 June 2019]

[47] Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV. Available from: https://clinicaltrials.gov/ct2/show/NCT03551444 [Last accessed on 27 June 2019]

[48] Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment (LONGHEAD). Available from: https://clinicaltrials.gov/ct2/show/NCT03551444 [Last accessed on 27 June 2019]

[49] Effect of DAAs on Behavior of HCC in HCV Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT03551444 [Last accessed on 27 June 2019]

[50] Direct Acting Antiviral-Post Authorization Safety Study. Available from: https://clinicaltrials.gov/ct2/show/NCT03551444 [Last accessed on 27 June 2019]

[51] EASLEASL recommendations on treatments of hepatitis C 2018..J Hepatol2018;69:461-511

[52] Pascasio JM,Ferrer MT,Rubin A.Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation..J Hepatol2017;67:1168-76

[53] Persico M,Aghemo A,Lleo A.High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma..Aliment Pharmacol Ther2018;47:1705-12

[54] Hassany M,Maged A,Asem N.Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact..Eur J Gastroenterol Hepatol2018;30:876-81

[55] Bas A,Gulsen F,Kabasakal L.Evaluation of liver stiffness after radioembolization by real-time shearwave TM elastography : preliminary study..Cardiovasc Intervent Radiol2014;38:957-63

[56] LLovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[57] Llovet JM,Lencioni R,Dufour JF.EASL - EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma..J Hepatol2012;56:908-43

[58] Heimbach JK,Finn RS,Abecassis MM.AASLD guidelines for the treatment of hepatocellular carcinoma..Hepatology2018;67:358-80

[59] Himmelsbach K,Baumert TF,Blum HE.New aspects of an anti-tumour drug: Sorafenib efficiently inhibits HCV replication..Gut2009;58:1644-53

[60] Bürckstümmer T,Lupberger J,Schmittel S.Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication..FEBS Lett2006;580:575-80

[61] Zona L,Sidahmed-Adrar N,Harris HJ.HRas signal transduction promotes hepatitis c virus cell entry by triggering assembly of the host tetraspanin receptor complex..Cell Host Microbe2013;13:302-13

[62] Menzel N,Hueging K,Frentzen A.MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles..PLoS Pathog2012;8:1-17 PMCID:PMC3406102

[63] Descamps V,Louandre C,Brochot E.The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro..Antiviral Res2015;118:93-102

[64] Cabrera R,Horne P,Soldevila-Pico C.The antiviral effect of sorafenib in hepatitis c-related hepatocellular carcinoma..Aliment Pharmacol Ther2013;37:91-7 PMCID:PMC3682667

[65] Ji F.Letter : the antiviral activity of sorafenib in patients with hepatitis C-related hepatocellular carcinoma..Aliment Pharmacol Ther2013;37:372-3

[66] Bruix J,Meinhardt G,De Sanctis Y.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies..J Hepatol2017;67:999-1008

[67] Llovet JM,Sia D.Molecular therapies and precision medicine for hepatocellular carcinoma..Nat Rev Clin Oncol2018;15:599-616

[68] Liverpool U. of. HEP Drug Interaction checker.

[69] Revuelta-Herrero JL,Matilla-Peña A,Sanjurjo-Sáez M.Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice..J Clin Pharm Ther2018;43:906-9

[70] Moreno-Cubero E.Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis..World J Gastroenterol2016;22:6469-83 PMCID:PMC4968127

[71] Gardiner D,Lawitz E,Ghalib R.A randomized, double-blind, placebo-controlled assessment of bms-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis c virus infection..PLoS One2013;8:1-11 PMCID:PMC3661719

[72] El-Khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502

[73] Zhu AX,Edeline J,Ogasawara S.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib ( KEYNOTE-224 ): a non-randomised, open-label phase 2 trial..Lancet Oncol2018;940-52:

[74] Mazouz S,Shoukry NH.Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C..Can Liver J2018;1:78-105

[75] Meissner EG,Higgins J,Prokunina O.Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis c virus infection..Hepatol Commun2017;1:586-94 PMCID:PMC5703427

[76] AASLD & IDSAAASLD/IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C..Clin Liver Dis (Hoboken)2018;12:117

[77] Kawaoka T,Teraoka Y,Honda F.Impact of hepatitis c virus eradication on the clinical outcome of patients with hepatitis c virus-related advanced hepatocellular carcinoma treated with sorafenib..Oncology2017;92:335-46

[78] Curry MP,Chung RT,Brown R Jr.Sofosbuvir and ribavirin prevent recurrence of hcv infection after liver transplantation: an open-label study..Gastroenterology2015;148:100-7

[79] Chang CY,Le A,Ahmed A.Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease..Medicine (Baltimore)2017;96:e6128 PMCID:PMC5313031